Weekly Stock Watch 14 Nov 2026: 22 Growth Stocks After Q2 FY27

Weekly stock watch for 14 Nov 2026: 22 Indian stocks with upcoming growth triggers after Q2 FY27 results, each screened on market cap and growth.

These stocks cleared our market-cap and growth checks this week, and each has at least one upcoming growth or re-rating trigger named in its latest company filings.

Divi's Laboratories (DIVISLAB): growth triggers and Q2 FY27 outlook

- Current price: Rs 11442.00 - Market cap: Rs 303749cr

Divi's Laboratories delivered a standout quarter with revenue up 37% and PAT surging 64% year-on-year, driven by a structural shift in business mix — Custom Synthesis now accounts for 62% of revenues versus roughly 50% historically, and alongside backward integration at its Kakinada facility, this pushed net material costs from ~40% to ~32% of sales, an ~800 basis-point improvement that management explicitly called structural rather than one-off. EBITDA margins have exceeded 40% for two consecutive quarters, well above the company's own 32–35% guidance band, signalling durable margin expansion rather than a cyclical blip.

Three major dedicated custom-synthesis programs are progressing through final validation, with one described as very close to commercialization and the remaining two expected to begin contributing revenues within the next one to two quarters, adding a visible near-term revenue catalyst. Meanwhile, Divi's is committing ₹2,000 crores annually in capacity, building toward a global top-three position in peptide (SPPS) manufacturing — a capability that deepens its moat with multinational innovator clients and positions the company to capture incremental CDMO mandates as global pharma supply chains continue to diversify away from single-source suppliers.

Management: "Apart from the three projects where one of them is very close to commercialization, other two we expect in the next one or two quarters, slowly the commercialization factor will come in." — Dr. Kiran S. Divi

Upcoming growth and re-rating triggers

- Order book execution: 3 dedicated CS projects nearing commercialisation: 1 'very close', 2 more in Q3–Q4 FY27 — incremental high-margin revenue not yet in numbers.

Steel Strips Wheels (SSWL): growth triggers and Q2 FY27 outlook

- Current price: Rs 567.00 - Market cap: Rs 8923cr - Individual/HNI bulk-or-block BUY in last 3mo: ALPHAGREP SECURITIES PRIVATE LIMITED, HRTI PRIVATE LIMITED, JUNOMONETA FINSOL PRIVATE LIMITED, PLUTUS WEALTH MANAGEMENT LLP, QE SECURITIES LLP

Steel Strips Wheels Limited delivered its strongest quarter in company history in Q2 FY27 — revenue up 61% year-on-year and PAT more than tripling — as a deliberate pivot toward aluminium alloy wheels, which carry roughly 40% higher EBITDA per wheel than steel, pushed EBITDA per wheel from ₹242 to ₹404 and expanded margins by 270 basis points to 12.3%. The company has already surpassed both its full-year FY27 revenue growth and profitability targets with two quarters still to go, and a zero-capex debottlenecking of its Mehsana alloy wheel plant in October added 10% more annualised capacity to meet demand that continues to run ahead of supply.

SSWL's position as the lowest-cost producer of aluminium and steel wheels globally outside of state-subsidised China is further insulated in Europe by anti-dumping duties on Chinese alloy wheels, while fresh commercial approvals from MAN, Scania, and Daimler — secured after a 12-year qualification process — open a meaningful new export order runway beginning Q4 FY27. Five separate institutional and HNI buyers transacted in the stock via bulk or block deals over the past three months, adding a noteworthy demand signal to what is already a structurally improving business.

Management: "EBITDA/wheel of ₹400+ is sustainable; ₹450–500 for FY28 is achievable, driven by product mix richness and automation-led cost reduction at upcoming facilities."

Upcoming growth and re-rating triggers

- Capacity expansion: Bhuj alloy wheel plant (1.2M wheels p.a.) starts April 2027, guided 80% utilisation FY28 and 100% within 3-4 months — directly lifts revenue. - Margin expansion: Management endorsed ₹450–500 EBITDA/wheel target for FY28, up from ₹404 in Q2 FY27, driven by mix richness and automation at new plants. - New product / new market: Aluminium knuckle enters commercial production at Bhuj in Q4 FY27 (Jan–Mar 2027) at 1.1M units annual capacity — an entirely new revenue stream. - New product / new market: Hot stamping line at Sambhajinagar (new segment) starting at sold-out capacity with a named Maharashtra OEM anchor and 2 more in pipeline.

Rolex Rings (ROLEXRINGS): growth triggers and Q2 FY27 outlook

- Current price: Rs 213.00 - Market cap: Rs 5597cr

Rolex Rings delivered its strongest quarter ever in Q2 FY27, with revenue up 43.5% and PAT up 68.2% year-on-year, fuelled by a deliberate shift away from commodity bearing rings toward higher-margin precision auto components, which now account for 54% of component sales versus 42% a year ago. That mix shift drove EBITDA margins up roughly 400 basis points to 24.2%, and management has guided a further 50–75 bps of margin expansion in FY28 as auto component volumes continue to scale.

The company enters the second half of FY27 with a healthy forward order book running at INR 120–125 crore per month, two new customer plant programs beginning supply in Q3–Q4, and US automotive revenue that more than doubled year-on-year as customers who had cut volumes through FY26 returned with meaningful orders. All of this sits on a completely debt-free balance sheet carrying INR 260 crore in cash — even after returning INR 180 crore to shareholders via a buyback — which provides management both flexibility to fund the next capacity expansion and confidence to explore defense and aerospace as an incremental growth avenue over the next 12–18 months.

Management: "Fiscal 2027 quarter two has been the strongest quarter in the history of the company, on revenue side, on margin side, on efficiency, and profitability." — MD Manesh Madeka (via CFO Hiren Doshi)

Upcoming growth and re-rating triggers

- Order book execution: Two new customer plants start supply in Q3 and early Q4 FY27; H2 order book at INR 120-125 Cr/month, lifting revenue run rate. - Margin expansion: Auto components mix rising from 54% toward 60%+; FY28 EBITDA margin guided 50-75 bps above FY27 as mix deepens. - Operating leverage: Utilization at 65-68% heading to 70-72% by FY27-end within flat capex; fixed costs spread over rising volumes boosts margins. - New product / new market: Defense and aerospace: initial approvals received; revenue expected within 12-18 months using existing forging facilities — a new segment.

Bhartiya International (BIL): growth triggers and Q2 FY27 outlook

- Current price: Rs 1125.00 - Market cap: Rs 1508cr

Bhartiya International Limited has delivered a rare combination of accelerating revenue and fast-expanding profitability: Q2FY27 revenue hit a record Rs 507 crore (+27% YoY) while half-year adjusted PAT nearly doubled (+94.7% YoY), with PAT margins widening 159 basis points as the prior capex cycle matures and depreciation falls sharply. The business carries genuine structural advantages — 70% of revenues come from brands that have partnered with BIL for over five years, the in-house tannery and Milan/London design studios create meaningful switching costs, and BIL's multi-country manufacturing footprint positions it squarely in the path of ongoing global sourcing diversification away from China.

Capital efficiency is visibly improving: ROCE expanded 320 basis points YoY to 12.7%, working capital days tightened from 209 to 185, and cash conversion (OCF/EBITDA) rose to 65%. A freshly completed capacity expansion and a pipeline of over US$45 million in identified revenue opportunities — from deepening existing brand relationships and cross-category expansion — give the growth story a clear near-term catalyst beyond the macro tailwind.

Management: "Rs 120 Cr total capex program expected to unlock Rs 1,000 Cr incremental revenue potential; capex-to-revenue ratio of Rs 8–10 incremental sales per Rs 1 of capex incurred."

Upcoming growth and re-rating triggers

- Capacity expansion: Rs 120 Cr capex across leather (+40%), textile (2-3x) and bags (2-3x) divisions targets Rs 1,000 Cr incremental revenue. - Operating leverage: Existing assets can support 20% more revenue with no incremental capex, spreading fixed costs over rising volume. - Recent development: Production lines enhanced and new sampling/product development centre launched H1FY27; CWIP jumped from Rs 3 Cr to Rs 23 Cr. - New product / new market: Apparel share rising from 15% (FY26) to 17% (H1FY27); US$10-15mn cross-category expansion pipeline in active discussions.

Cupid (CUPID): growth triggers and Q2 FY27 outlook

- Current price: Rs 378.00 - Market cap: Rs 50801cr

Cupid Limited delivered revenue growth of 132% and PAT growth of 133% year-on-year, underpinned by a genuinely rare competitive moat: it is the only company globally to hold WHO/UNFPA prequalification for both male and female condoms, which is a mandatory prerequisite for the largest institutional government and UN tenders — a barrier that takes years and significant capital to replicate. EBITDA margins have expanded steadily from 17.3% in FY22 to 33.5% in H1 FY27, driven by a 10% price increase implemented across the entire export portfolio, strong operating leverage on rapidly growing revenues, and a mix shift toward higher-margin branded domestic FMCG products.

For the first time, domestic Indian sales now account for two-thirds of revenue, accelerated by an exclusive 425-store V2 Retail partnership targeting approximately ₹400 crore over the next twelve months alongside the Style Baazar ecosystem. With the new Palava facility set to commission in Q3 FY27 — adding roughly 2.6x the current Sinnar capacity — the business has a clear path to another leg of operating leverage as volumes scale into already-established institutional and retail channels, while management has simultaneously upward-revised its FY27 revenue guidance by 47% to ₹880 crore.

Management: "We expect H2 FY27 to be stronger than H1, as Palava is to be commissioned in Q3 and both partnerships scale up." — MD Aditya Kumar Halwasiya

Upcoming growth and re-rating triggers

- Capacity expansion: Palava Plant (1.7L sq ft) targeting Q3 FY27 commissioning; adds 770M male condoms p.a., taking total capacity to 1.25B (2.6x) for H2 scale - New store openings: 425+ V2 Retail stores going live mid-Dec 2026 with 400 sq ft dedicated Cupid space; management projects ~₹400 Cr revenue in next 12 months - Order book execution: Style Baazar (290+ stores) ramping; ₹200 Cr incremental FY27 revenue guided; 56 Lakh warrants still pending, adding ~₹138 Cr equity inflow - Capacity expansion: IVD daily capacity doubling to 8L kits by end-2027; CE cert opens EU/multilateral tenders; sizeable State Govt orders expected in FY27 - New product / new market: Nitrile female condom in development since Mar 2026 at 25-35% ASP premium to latex; targets a category historically served by only one manufacturer globally

Panache Digilife (PANACHE): growth triggers and Q2 FY27 outlook

- Current price: Rs 757.00 - Market cap: Rs 1213cr

Panache Digilife, a Mumbai-based electronics design and manufacturing company, posted revenue growth of 108% and PAT growth of 220% year-on-year, with EBITDA margins expanding over 313 basis points to 9.6% — a direct result of its deliberate shift from low-margin contract manufacturing toward higher-margin products it designs in-house. The company is one of only a handful of Intel-recognised ODM partners in India, a 20-year relationship that gives it priority chip access when global supplies tighten — a real competitive edge in a volatile component market.

With approximately 40% spare capacity already available within its existing factory, it can grow revenue meaningfully without large near-term capital spending, and management has confirmed that the seasonally stronger second half of the year is still ahead. Return on capital employed has surged from 13.6% to 25.8% over two years, and the cash conversion cycle has tightened from 172 days to 68 days — signs of a business that is not just growing fast but becoming structurally more efficient as it scales.

Management: "Our relationship with Intel goes for more than two decades now. I think we are one of the oldest Intel partners in India... we are one of the ODMs."

Upcoming growth and re-rating triggers

- Order book execution: 36-month telecom order via Panache Newage Technology delivers revenue every quarter for 3 years — a durable, recurring stream outside core manufacturing. - Operating leverage: H2 is seasonally the larger half; with 40% spare capacity in existing plant, incremental H2 revenue drops through on a largely fixed cost base. - Margin expansion: DLM (5–20%+ margins) is being grown as a share of the mix; EBITDA already expanded 313 bps YoY and management is guiding it higher via DLM. - New product / new market: Quantron (HK subsidiary) has begun Phase 1 entry into Asian and emerging markets — a new revenue geography not yet in the numbers. - Recent development: Windows 10 EOL is forcing enterprise-wide PC refresh; Panache as an Intel ODM partner is positioned to capture the AI-PC upgrade cycle.

SBC Exports (SBC): growth triggers and Q2 FY27 outlook

- Current price: Rs 70.30 - Market cap: Rs 3348cr - Individual/HNI bulk-or-block BUY in last 3mo: ACME CAPITAL MARKET LIMITED, HRTI PRIVATE LIMITED

SBC Exports Limited, a Ghaziabad-based company spanning garments manufacturing, manpower services, and IT support, has delivered one of the sharper growth prints in its category this season — standalone revenue more than doubled year-on-year to Rs 138 crore in Q2FY27, while PAT grew 41% to Rs 10.8 crore, pushing H1FY27 cumulative PAT to Rs 20.3 crore versus Rs 13.9 crore in the same period last year. Capital work-in-progress has been climbing, pointing to active capacity addition that could underpin the next leg of revenue growth. Four bulk or block buy transactions by HNI entities including ACME Capital Market and HRTI Private Limited over the last three months indicate informed market participants are building positions.

The key risk to watch is margin compression — raw material costs have risen to roughly 88% of revenue from 78% a year ago, squeezing EBITDA margins by around 670 basis points even as the top line scales rapidly. Investors comfortable with that cost-structure evolution, and willing to track whether volume growth eventually restores operating leverage, may find the current trajectory worth a closer look.

Upcoming growth and re-rating triggers

- Margin expansion: Raw material costs swelled to ~88% of revenue vs ~78% YoY, compressing EBITDA ~670 bps; any normalisation directly flows to PAT. - Operating leverage: Revenue has more than doubled YoY (+113%) and grown 30% QoQ; rising volumes should spread fixed costs and improve margins ahead. - Capacity expansion: CWIP rose from Rs 15.20 Cr to Rs 16.46 Cr indicating fresh capex underway; commissioning would add productive capacity and revenue. - Recent development: Four Labour Codes notified Nov 2025 assessed for manpower segment — no material financial impact foreseen, clearing a key overhang. - Other re-rating trigger: H1FY27 PAT Rs 20.30 Cr (+46% YoY) on Rs 244 Cr revenue; FY27 annualised earnings run-rate likely not yet fully priced in.

Spectrum Electrical Industries (SPECTRUM): growth triggers and Q2 FY27 outlook

- Current price: Rs 4509.00 - Market cap: Rs 7704cr

Spectrum Electrical Industries, a Maharashtra-based electrical manufacturer, delivered standout Q2FY27 results with revenue up 64% and PAT more than doubling year-on-year, while EBITDA margins expanded roughly 650 basis points to ~19% — a signal that the business is not just growing fast but becoming structurally more profitable. Notably, the company's first-half FY27 profit alone already equals 74% of its entire FY26 annual profit, suggesting the growth trajectory is steepening rather than flattening.

A recently completed preferential share allotment has fortified the balance sheet, with cash surging from just Rs 7.7 crore to over Rs 260 crore, giving the company ample firepower for its ongoing capacity build-out evidenced by Rs 97 crore of capital work-in-progress at its facilities. With fresh manufacturing assets being capitalised and a strengthened equity base in place, Spectrum appears well-positioned to convert its revenue momentum into higher earnings as the new capacity comes online.

Upcoming growth and re-rating triggers

- Capacity expansion: Rs 97.44 Cr CWIP indicates large-scale manufacturing capacity still under construction; will drive future revenue when commissioned. - Operating leverage: PAT growing at 2x the rate of revenue (132.7% vs 64.4% YoY) as fixed costs spread over rising volumes. - Margin expansion: EBITDA margin expanded ~650 bps YoY to 19.2% in Q2FY27; PAT margin up ~290 bps — expanding trajectory with scale. - Recent development: Rs 260.73 Cr fresh capital from preferential issue to be deployed into expansion; CRISIL confirms no deviation in fund use. - Capacity expansion: Rs 63 Cr of new assets already commissioned in H1FY27; fresh capacity running and revenue ramping from it.

Kalyan Jewellers (KALYANKJIL): growth triggers and Q2 FY27 outlook

- Current price: Rs 697.00 - Market cap: Rs 71983cr - Individual/HNI bulk-or-block BUY in last 3mo: GRAVITON RESEARCH CAPITAL LLP

Kalyan Jewellers posted 31.6% revenue growth and a 61.8% jump in PAT year-on-year, with the standout structural driver being its accelerating pivot from company-owned stores to a franchise-owned, company-operated (FOCO) model that strips out working-capital drag on gold inventory and mechanically lifts return ratios as the mix shifts. With over 1,200 showrooms now spanning 33 states and a Phase IV expansion roadmap underway, the company is growing its physical footprint at scale while keeping its own capital largely on the sidelines — a rare combination in brick-and-mortar retail.

Margin expansion is further supported by a deliberate push into studded and diamond jewellery to premiumise the revenue mix, while Candere, its online platform, adds a capital-light digital growth vector on top of the core store network. Graviton Research Capital LLP added a bulk position in the last three months, an institutional vote of confidence in the franchise-led growth thesis.

Upcoming growth and re-rating triggers

- Margin expansion: FOCO model shift removes company-owned gold inventory burden, structurally compressing working capital and lifting return ratios as franchise share grows. - Operating leverage: Phase III/IV roadmap explicitly targets operating leverage as fixed infrastructure costs spread over a rising FOCO store base. - New store openings: Phase IV strategic roadmap signals next wave of franchise-led geographic or format expansion beyond 1,203 current showrooms. - New product / new market: Candere online jewellery platform being scaled as a standalone Kalyan company, adding a separate high-growth digital revenue vector. - Other re-rating trigger: Management separately tracking Gold vs Studded revenue signals a deliberate premiumisation push toward higher-margin studded jewellery.

Meesho (MEESHO): growth triggers and Q2 FY27 outlook

- Current price: Rs 257.00 - Market cap: Rs 119049cr - Individual/HNI bulk-or-block BUY in last 3mo: AAGAM INVESTMENTS, BAJAJ LIFE INSURANCE LIMITED, BNP PARIBAS FINANCIAL MARKETS, SOCIETE GENERALE, VIRIDIAN ASIA OPPORTUNITIES MASTER FUND

Meesho delivered revenue growth of 80.5% and a near-8x surge in PAT year-over-year, powered by a marketplace that is deepening its structural hold on India's Tier 2/3 and rural consumers — a segment large-cap e-commerce rivals have chronically under-served. Annual transacting users rose 29% YoY in Q1 FY27 and order frequency grew 9%, while the cost per delivered order actually fell despite a fuel price hike and minimum-wage increases absorbed in the same quarter, signaling that the in-house Valmo logistics arm is becoming a genuine, durable cost moat. Contribution margins are expanding on two concurrent drivers: a recovering logistics spread and rapidly growing advertising revenue — now used by roughly two-thirds of GMV-contributing sellers — that drops almost entirely to the bottom line at negligible incremental cost.

Five mutual fund buy transactions and five bulk or block purchases by institutional names including BNP Paribas Financial Markets, Societe Generale, Bajaj Life Insurance, and Viridian Asia Opportunities in the past three months suggest sophisticated capital is actively building a position. The acquisition of Kirana Club and a nascent local logistics network for perishables add early-stage optionality in B2B commerce and grocery, extending the long-run TAM well beyond the core consumer marketplace.

Management: "Targeting 25% annual growth in total sales over the next five years."

Upcoming growth and re-rating triggers

- Margin expansion: Logistics spread restored faster than cost-offsets; analyst-confirmed supra-cost margin expansion not refuted by management. - Operating leverage: 2/3 of sellers now on ads and expanding catalog coverage; ad revenue drops directly to contribution margin with minimal incremental cost. - Margin expansion: Meesho Mall branded sellers growing faster than platform average with structurally higher ad revenue per NMV, shifting revenue mix upward. - Other re-rating trigger: Annual Blockbuster festive sale shifts to October 2026 (Q3 FY27), concentrating a large GMV event that will visibly boost Q3 numbers. - Operating leverage: ADU +29% YoY and order frequency +9% YoY over stabilized logistics; cost per order fell ₹1 QoQ despite fuel and wage hikes.

Asahi India Glass (ASAHIINDIA): growth triggers and Q2 FY27 outlook

- Current price: Rs 1110.00 - Market cap: Rs 28303cr

Asahi India Glass delivered its best-ever quarterly results in Q2FY27, with revenue up 36.2% YoY to ₹1,474 Cr while PAT surged ~260% YoY to ₹171 Cr — a rare combination of top-line scale and explosive bottom-line leverage driven by operating efficiency rather than a one-time windfall. EBITDA margins expanded roughly 500–610 basis points YoY to ~22–23.5%, reflecting the company's deliberate pivot toward higher-value-added glass products (tempered, laminated, solar-control, HUD glass) across both its automotive and architectural segments.

The Float Glass division was the standout, with segment profit tripling YoY as the company's F2 furnace ran at full utilisation after being under cold-repair in the year-ago period, and new Phase III tempered capacity at Patan and expanded laminated capacity at Chennai lay the groundwork for the next leg of margin improvement. With ~80% share of India's passenger vehicle glass market, declining finance costs (down 25.5% YoY as debt is being repaid), and government Minimum Import Price protection shielding the domestic glass industry, AIS appears to be in a structurally improving earnings trajectory.

Upcoming growth and re-rating triggers

- Operating leverage: Patan Phase III + Chennai laminated ramp-up costs currently drag Automotive margins; stabilization in H2FY27 should restore and expand margins. - New product / new market: Ongoing mix shift to HUD, solar-control, laminated glass in both segments; Float Glass product mix already drove 246.6% profit surge. - Order book execution: 12 new OEM car model launches supported in Q2FY27 each add recurring multi-year automotive glass supply contracts to the revenue base. - Margin expansion: MIP framework shields domestic pricing from dumped imports, letting AIS sustain premium pricing as Float Glass and Automotive volumes scale.

Emcure Pharmaceuticals (EMCURE): growth triggers and Q2 FY27 outlook

- Current price: Rs 2362.00 - Market cap: Rs 44804cr

Emcure Pharmaceuticals has delivered a standout quarter with revenue up 32% and profit after tax more than doubling year-on-year, underpinned by simultaneous acceleration in both its India domestic business and its fast-growing international complex injectables franchise. EBITDA margins expanded 100 basis points to 20.4% — a structural improvement management attributes to operating leverage as revenue growth consistently outpaces SG&A — and the company has upgraded its full-year FY27 revenue growth guidance from "mid-teens" to "exceeding 20%." The international story is particularly compelling: its liposomal amphotericin B franchise has reached 50% penetration across Europe with roughly 20 markets still untapped, and Brazil, Mexico, and Colombia launches are imminent, while treprostinil — a high-value pulmonary hypertension drug with limited competition — is lined up as the next significant European contributor over the coming year.

Domestically, the semaglutide biosimilar Poviztra has already reached 4 in India's obesity segment within months of launch, with a Canada regulatory filing expected before fiscal year-end, adding durable GLP-1 optionality that most Indian pharma peers lack. Three mutual fund buy deals in the past three months reflect growing institutional recognition of this multi-geography, pipeline-rich growth story.

Management: "Profitability outpaced revenue growth, EBITDA rose 31% to INR575 crores and EBITDA margins expanded by about 100 basis points to 20.4%, driven by productivity gains and operating leverage." — MD Satish Mehta

Upcoming growth and re-rating triggers

- New product / new market: Lipo ampho B approved in Brazil, Mexico, Colombia; batches in production; H2FY27 launches across multiple new ROW market buckets imminent. - New product / new market: Treprostinil for PAH is next major Europe product — limited competition, high-margin, expected to contribute meaningfully within 12 months. - Operating leverage: FY27 revenue growth upgraded to 20%; EBITDA margin guided to upper end of 75–100 bps improvement as SG&A grows slower than revenue. - New product / new market: Semaglutide supply to Quebec (Dr. Reddy's) in Nov 2026; Canada regulatory filing within FY27 — entering new high-value GLP-1/obesity market. - Recent development: Lenacapavir long-acting HIV injectable got India SEC positive rec; WHO and US FDA dossiers filed; margin-accretive vs current ARV mix.

Manaksia Coated Metals (MANAKCOAT): growth triggers and Q2 FY27 outlook

- Current price: Rs 172.00 - Market cap: Rs 2038cr

Manaksia Coated Metals (MANAKCOAT) posted record quarterly revenue and profit in Q2FY27, with revenue up 45% and PAT up 36% year-on-year, driven by a 7.6% sequential jump in realization per ton to Rs. 95,291 as the company shifts its product mix toward higher-margin Pre-Painted and specialty Alu-Zinc steel. EBITDA per ton expanded from Rs. 10,411 to Rs. 11,536 quarter-on-quarter, reflecting a combination of disciplined pricing, adoption of break-bulk shipping to cut freight costs on European shipments, and a surge in Alu-Zinc exports — up 457% sequentially — as new markets in South America and the Caribbean gain traction.

A structural geographic moat — the Kutch factory sits just 40–50 km from Kandla and Mundra ports — keeps the company's export cost structure below any inland Indian rival, and India received the most favourable treatment among all exporting nations in the latest EU safeguard quota review, cementing its competitive position in its dominant market. A second Colour Coating Line expected to commission in Q3FY27 will expand Pre-Painted Steel capacity by 174%, and Phase 2 backward integration into Cold-Rolled Coils is projected to add a further Rs. 1,500–1,700 per ton to EBITDA while cutting inventory days roughly in half — both catalysts supporting management's FY29 vision to triple output, revenue, and EBITDA.

Management: "These initiatives form an important part of our broader FY '29 vision to triple output revenue and EBITDA." — Karan Agrawal, WTD

Upcoming growth and re-rating triggers

- Capacity expansion: Second CCL commissioning in Q3FY27 grows Pre-Painted Steel capacity 174%, from 86,000 to 2,36,000 MT/annum — central to revenue tripling vision. - Margin expansion: 7 MW captive solar plant targeting Q3FY27 grid connectivity will offset 50–55% of Kutch facility grid power, reducing energy cost structurally. - New product / new market: Alu-Zinc export volumes surged 457% QoQ after entry into South and Central America — a new geography whose ramp is still in early innings. - Order book execution: Rs. 525 Cr order book (Rs. 420 Cr export) covers 5 months of execution, with spot domestic orders additive monthly and H2FY27 run-rate guided slightly higher.

Alembic Pharmaceuticals (APLLTD): growth triggers and Q2 FY27 outlook

- Current price: Rs 1030.00 - Market cap: Rs 20249cr

Alembic Pharmaceuticals delivered 33% revenue growth and 128% PAT growth on the back of a 520 basis point EBITDA margin expansion (from 17% to 22.2% YoY), as operating leverage from a now-complete greenfield capex cycle compounds with a richer product mix skewed toward higher-margin first-to-file and specialty launches. U.S. Generics — the standout growth engine — surged 72% YoY in Q2 FY27, and crucially the base portfolio excluding new launches still grew 23%, pointing to broad-based volume momentum rather than a single-product story.

Management has raised full-year revenue growth guidance to 20–25% (from mid-teens), underpinned by a pipeline of over 30 U.S. launches in the next 18 months — roughly a quarter carrying first-to-file or Day-1 exclusivity status — plus a capital-efficient DifGen partnership targeting 20+ complex generics across an approximately $5 billion U.S. reference market. With the heavy capex cycle behind it, the company's focus shifts to sweating existing assets via debottlenecking, a structural setup that should drive improving asset turns and returns on capital well beyond any single exclusivity window.

Management: "With major capex cycle now behind us, our focus is on driving returns from the existing asset base through debottlenecking and incremental line additions without significant new greenfield investment." — CFO G. Krishnan

Upcoming growth and re-rating triggers

- Order book execution: 30+ U.S. generic launches planned over 18 months; ~25% are FTF/Day-1, generating margin uplift during exclusivity windows - Operating leverage: Greenfield capex cycle complete; debottlenecking sweats existing assets, driving EBITDA margins higher with minimal new capital outlay - Other re-rating trigger: India Human Health targeting IPM-level double-digit growth within 2-3 quarters (Q3-Q4 FY27); specialty already outpacing IPM by 200 bps - Other re-rating trigger: FY27 consolidated revenue guidance raised sharply to 20-25% (from mid-teens); U.S. guided up to 40% YoY growth

The Indian Hotels Company (INDHOTEL): growth triggers and Q2 FY27 outlook

- Current price: Rs 890.00 - Market cap: Rs 126728cr

IHCL, India's largest hotel company and the brand behind the iconic Taj chain, has delivered revenue growth of 26% and PAT growth of 36% year-on-year — its 18th consecutive quarter of record performance — underpinned by genuine operational improvement rather than one-off gains. Occupancy surged 700 basis points to 82% in Q2 FY27 while stand-alone RevPAR grew 28%, and stand-alone EBITDA margins expanded 400 basis points to 38.9% even as the quarter absorbed new payroll costs and regulatory changes, confirming the expansion is structural and driven by operating leverage, a fast-growing MICE business, and high-margin management fee income.

The company's capital-light model — 94% of its 34,800+ key pipeline is management contracts or leases — means scale compounds without proportional balance-sheet risk, and management fee income is internally targeted to reach INR 1,000 crore within approximately two years. Full-year consolidated revenue growth guidance has been upgraded by 300 basis points to 15–17%, with the pending Oriental Hotels merger poised to add a further 6–7% to stand-alone operating revenue in FY28, making the near-term earnings trajectory look unusually well-supported.

Management: 'What do you mean can be, it will be better' — MD Puneet Chhatwal, directly on whether FY28 will surpass FY27, citing new hotel openings, the OHL merger, and TajSATS base normalization.

Upcoming growth and re-rating triggers

- Recent development: OHL merger (April 1, 2027) adds 6-7% to standalone revenue in FY28; deferred capex on OHL hotels now activated by IHCL's asset-management team. - Other re-rating trigger: CFO leaked internal management-fee target of INR 1,000 Cr in ~2 years vs public 'high-teens CAGR'; formal guidance revision signalled at Q3 results. - Operating leverage: FY28 wedding calendar at ~95 nights vs normal 60-65 is a quantified, confirmed MICE demand uplift over largely fixed hotel costs. - Capacity expansion: Accelerate 2030's 700-hotel target crossed before FY27 year-end; a higher revised target to be announced mid-November 2026, resetting investor growth expectations. - New store openings: Ginger targeting 150 operational hotels by March 2027 from 100 now, with 75 Clarks signings providing ready pipeline — all at 40% EBITDA margin.

Navin Fluorine International (NAVINFLUOR): growth triggers and Q2 FY27 outlook

- Current price: Rs 10002.00 - Market cap: Rs 51325cr

Navin Fluorine International delivered exceptional H1FY27 results, with revenue up 51% year-on-year and PAT crossing INR 500 crores — a 93% jump — as its refrigerant gases, specialty chemicals, and pharmaceutical manufacturing businesses all contributed simultaneously. EBITDA margins expanded 367 basis points to 34.2%, driven by operating leverage and ongoing operational efficiencies rather than one-off pricing luck, suggesting the profitability step-up is structural. The HFO refrigerant supply agreement with a Honeywell affiliate was extended four additional years to December 2032, adding approximately USD 180 million in revenue potential and removing near-term revenue cliff concerns that had been an investor overhang.

Freshly debottlenecked specialty chemicals capacity at Dahej was commissioned in September 2026, but those incremental volumes have not yet appeared in reported numbers — implying an organic growth lift heading into H2FY27. With CDMO revenues on track for USD 100 million this fiscal year and an Advanced Materials vertical being incubated for data centers and defense, the growth vectors here look unusually well-stacked.

Management: "really a solid EBITDA that cannot come only from pricing — that has to continuously come from the efficiencies and the improvements we drive" — CFO, Q2FY27 concall

Upcoming growth and re-rating triggers

- Capacity expansion: MPP debottlenecking at Dahej commissioned Sep 2026; incremental specialty volumes NOT yet in Q2 numbers — uplift flows into Q3 FY27 onwards. - Capacity expansion: R32 plant on track for Q3 FY27 commissioning; incremental HPP revenue in Q3 with full ramp in Q4 FY27. - Capacity expansion: cGMP-4 Phase 2 (INR 125 Cr capex) operational by Q4 FY27; combined Phase 1+2 target peak revenue INR 900-1,000 Cr by FY28-29. - New product / new market: Chemours advanced immersion cooling fluid commissioning Q3 FY27; product qualified with French OEM 2CRSi, purchase orders already in hand. - Recent development: CDMO molecule received regulatory approval in China and is on fast track for US FDA approval; darolutamide pursuing label expansion for wider use.

Neogen Chemicals (NEOGEN): growth triggers and Q2 FY27 outlook

- Current price: Rs 2809.00 - Market cap: Rs 8438cr

Neogen Chemicals is delivering a rare combination of explosive growth and structural compounding: consolidated revenue rose 42% YoY and PAT more than doubled in Q2FY27, powered by a 640% surge in battery chemicals revenue as its Neogen Ionics subsidiary ramps electrolyte salt production. The company's non-FEOC compliance positions it as one of only four or five qualified global suppliers for US battery manufacturers seeking 45x IRA tax credits — a regulatory moat that effectively locks out Chinese competitors starting calendar 2027, with three of five US electrolyte producers already completing site audits at Dahej and two on commercial supply.

The core organolithium business is itself running at full 300 MT capacity with the board approving a doubling to 600 MT, while standalone EBITDA margins hold at a healthy 18.6% and management guides 18-20%, suggesting the margin expansion story is structural rather than cyclical. A 6.5x oversubscribed QIP of INR 600 crore, a CRISIL rating upgrade to A- Stable, and an accelerating INR 316 crore insurance settlement collectively reinforce balance sheet credibility heading into what could be the company's most consequential revenue ramp — targeting INR 1,000 crore+ in battery chemicals alone by FY28.

Management: "We do not see a challenge in crossing INR 1,000 crore plus revenue [from battery chemicals in FY28]. The INR 1,000 crore+ remains." — MD Dr. Harin Kanani

Upcoming growth and re-rating triggers

- New product / new market: US non-FEOC 45x tax credit mandate forces American cell makers away from China to Neogen from calendar 2027; 2 already on commercial supply. - Order book execution: Battery chemicals Q3FY27 revenue guided materially above Q2's INR 37 Cr, backed by confirmed purchase orders already in hand. - Capacity expansion: Dahej rebuilt plant trials underway; commercial production imminent in Q3FY27, releasing blocked CSM project revenues in following quarters. - Capacity expansion: Organolithium capacity doubling 300→600 MT pa at Patancheru, Board-approved INR 45 Cr capex, driven by new approvals in agro, semiconductors, specialty polymers. - Operating leverage: Salt capacity hitting 70-80% utilization in FY28 reverses Neogen Ionics fixed-cost drag, lifting consolidated margins toward 20%+.

Saregama India (SAREGAMA): growth triggers and Q2 FY27 outlook

- Current price: Rs 653.00 - Market cap: Rs 12599cr

Saregama posted 32% revenue growth and 29% PAT growth in its latest quarter, but the more compelling signal is operating leverage finally flowing through: the music vertical's EBIT margin expanded 700 basis points year-over-year to 55.4%, as content acquired in FY24–FY26 has matured to the point where incremental revenue far exceeds its ongoing amortization cost — exactly the inflection management had signposted three years ago. With management guiding for 60–65% EBITDA margins in the music vertical over the medium term, further expansion is still ahead.

Saregama's moat is structurally difficult to replicate: a catalog of 180,000+ songs protected by 55–75-year copyright terms generates royalty income for decades at near-zero incremental cost, in a market — India — that accounts for just 1% of global recorded music revenue despite holding 18% of the world's population. A strong H2FY27 album pipeline headlined by Sanjay Leela Bhansali's Love & War adds a near-term earnings catalyst to an already-improving margin story.

Management: Music vertical EBIT margin guided to 60–65% EBITDA on a medium-term basis; FY24–FY26 content investments are now entering their positive-margin phase, arriving on schedule as guided.

Upcoming growth and re-rating triggers

- Order book execution: 4 named blockbuster film albums due H2FY27: Love & War (SLB Q4), Seyon, Naagzilla (Dharma/Kartik), Tiger Shroff — set to spike licensing revenue - Recent development: INR 100+ Cr customer advances on multi-year licensing deals already on balance sheet in H1FY27, to flow into revenue recognition over coming quarters - Recent development: Pocket Aces (subsidiary) moves from break-even in FY26 to profitability in FY27, reducing drag on consolidated P&L

Tanla Platforms (TANLA): growth triggers and Q2 FY27 outlook

- Current price: Rs 733.00 - Market cap: Rs 9721cr

Tanla Platforms is delivering its sixth consecutive quarter of sequential revenue growth, with revenues expanding 32.9% year-on-year and profit after tax surging 43.9% YoY — a rare combination of scale and accelerating earnings in Indian tech. The company's ~35% market share in India's CPaaS market is anchored by deep relationships with the country's largest banks, insurers, and financial services firms, and a Net Revenue Retention rate of 119% confirms that existing customers are spending meaningfully more each year.

The shift toward higher-value OTT channels is gaining real momentum — 48% of new customers in the latest quarter were onboarded via WhatsApp and RCS — broadening the revenue mix beyond legacy SMS. Free cash flow came in at ₹231.6 crore, an exceptional 158% of reported PAT, while debtor days tightened sharply from 79 to 63, all on a debt-free balance sheet with ₹1,447 crore in total liquidity.

Upcoming growth and re-rating triggers

- Margin expansion: OTT/RCS mix shift has lifted Enterprise Comms gross margin from 17.9% (Q1 FY26) to ~20%; 48% of new Q2 customers via these higher-margin channels. - New product / new market: Wisely.ai R&D pipeline growing (₹66.2 Cr WIP vs ₹59.3 Cr); new features converting to SaaS revenue at near-100% gross margins. - Recent development: ValueFirst overseas consolidated in H1 FY27 with ₹7.8 Cr invested to build international CPaaS ops; margin drag reverses as scale improves. - Operating leverage: High-value customer cohort (₹10 Mn annualised) grew from 357 to 420 YoY with revenue up 24.1%, while indirect costs held steady at ~10% of revenue. - Other re-rating trigger: Customers with annualised revenue ₹500 Mn grew 42.5% YoY driven by BFSI; NRR of 119% signals compounding wallet-share expansion within existing base.

International Gemological Institute (IGIL): growth triggers and Q2 FY27 outlook

- Current price: Rs 439.00 - Market cap: Rs 18967cr

IGI Limited, the world's leading certifier of lab-grown diamonds, delivered its best quarter ever in Q2FY27 — posting all-time highs in volumes (4.35 million certificates), revenue, EBITDA, and PAT, with revenue up 27% and profit up 22% year-on-year. The company's first-mover position in lab-grown diamond certification (dating to 2005) is turning into a durable earnings engine: LGD loose certification grew 37% and LGD jewelry grew 47% year-on-year, while competitor GIA's decision to abandon full 4Cs grading for lab-grown diamonds is pushing more trade clients toward IGI as the de facto standard.

Operating leverage is structural — EBITDA margins expanded 340 basis points to 61.4% as the business scaled without proportionate cost additions — and new laboratories in Italy, Saudi Arabia, and Botswana signal further geographic reach. Management upgraded its full-year guidance after H1 alone beat prior annual targets, and AI-based grading tools are now live, allowing the same teams to process more certificates while maintaining quality standards.

Management: "This business has operating leverages which translates to EBITDA growth, which normally is faster than the revenue growth."

Upcoming growth and re-rating triggers

- Other re-rating trigger: Full-year guide beaten in H1; raised to H1-like delivery, meaning H2 consensus estimates need significant upward revision. - Operating leverage: EBITDA grew 39% vs revenue 31% in Q2FY27; management confirmed this outgrowth is structural every quarter, not a one-off. - Capacity expansion: Saudi Arabia lab in preparation contributes zero revenue today; launch adds a new high-margin geography to the global network. - New product / new market: AGL colored stone certification expanding from US-only to global markets; colored stones segment grew 331% YoY in Q2 (partly from AGL consolidation). - Other re-rating trigger: Indian LGD reactor capacity doubling in 3 years creates structural volume tailwind, feeding IGI's dominant LGD certification franchise.

Roto Pumps (ROTO): growth triggers and Q2 FY27 outlook

- Current price: Rs 73.90 - Market cap: Rs 1393cr

Roto Pumps delivered its strongest quarter on record in Q2FY27, with standalone revenue surging 55.6% YoY to Rs. 75.86 Cr while PAT more than quadrupled to Rs. 14.75 Cr (+308% YoY), expanding PAT margins from 7.4% to 19.4% — a sign of meaningful operating leverage kicking in as the business scales. EBITDA margins widened by roughly 1,100 basis points YoY to ~30.5%, and the company enters this period effectively debt-free at the non-current level, giving it a clean balance sheet to fund growth. On the expansion front, the company is actively capitalising capex — CWIP declined from Rs. 17.66 Cr to Rs. 9.92 Cr as fresh capacity flows into fixed assets, with PPE rising Rs. 13.1 Cr in H1FY27 alone.

Strategically, the newly launched HYGENIX Series of certified hygienic pumps targets food, dairy, beverage, and pharmaceutical customers — segments with strict specifications that typically command higher margins and stickier repeat business through spares and service. With international branches already contributing ~30% of quarterly revenue and a nascent high-margin product line in its early innings, the near-term earnings trajectory looks well-supported by both volume and mix improvement.

Upcoming growth and re-rating triggers

- New product / new market: HYGENIX Series (hygienic PC & Twin Screw pumps) launched Sep 2026 targeting food/dairy/pharma — higher-spec, higher-margin segment entirely new for Roto. - Recent development: 3-A and EHEDG certifications for HYGENIX pumps in process; approval will unlock regulated food/pharma customer qualifications and accelerate order conversion. - Capacity expansion: Ongoing capex being capitalized: PPE up Rs.13.1 Cr in H1FY27 with Rs.9.92 Cr CWIP still to convert, adding production capacity to sustain revenue scale-up. - Operating leverage: Revenue +55.6% YoY drove PAT +308% YoY as fixed costs spread over rising volumes; EBITDA margin expanded ~1,100 bps YoY to 30.5% — dynamic still playing out. - Margin expansion: Shift toward HYGENIX stainless-steel hygienic pumps for regulated industries (food/pharma/cosmetics) expected to structurally lift blended margins beyond current 30.5% EBITDA.

Algoquant Fintech (ALGOQUANT): growth triggers and Q1 FY27 outlook

- Current price: Rs 84.20 - Market cap: Rs 2367cr

Algoquant Fintech, a GIFT City-based proprietary trading and broking firm, delivered a standout Q1FY27 with revenue climbing ~43% year-on-year to Rs. 77.87 crore while PAT surged ~263% to Rs. 16.52 crore — an earnings inflection powered almost entirely by its proprietary trading desk, which posted a 49% jump in fair-value gains to Rs. 69.20 crore. The operating leverage story is the headline: PAT margins nearly tripled from 8.4% to 21.2% in a single year, and EBITDA margins widened from ~17% to ~34%, meaning the company now converts roughly one-third of every revenue rupee into operating profit.

Sequential momentum is equally solid — PBT grew 36.6% quarter-on-quarter and EPS jumped from Rs. 0.16 to Rs. 0.59 year-on-year, a nearly 4x earnings-per-share expansion in twelve months. The key caveat is the firm's near-complete dependence on proprietary trading (89% of revenue), a model whose earnings can be volatile, but for investors comfortable with that profile, the Q1FY27 numbers make a compelling case for a closer look.

Upcoming growth and re-rating triggers

- New product / new market: Three global/offshore subsidiaries (IFSC, Global, Capital) all reporting nil revenue in Q1FY27 — any ramp-up is pure incremental upside not in numbers. - Operating leverage: Operating expenses grew only 15.7% YoY vs revenue +42.9%, lifting EBITDA margin from ~17.4% to ~33.7%; fixed-cost absorption trend intact. - Other re-rating trigger: Finance costs +79% YoY signals a materially larger proprietary trading book deployed; higher capital base can drive proportionally larger absolute trading gains. - Margin expansion: PAT margin nearly tripled to 21.2% from 8.4% YoY and PBT surged 36.6% QoQ to Rs. 22.16 Cr, showing momentum beyond seasonal base. - Recent development: Effective tax rate fell sharply to 25.4% from 31.6% YoY — a ~6pp drop that meaningfully amplifies PAT growth on any incremental PBT.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.